Author:
Krakauer Marcio,Gómez Ana M.,Almeda-Valdes Paloma,Manrique Helard,Ruiz Morosini María Lidia,Godoy Jorquera Gonzalo,Nunes Salles João Eduardo,Sanhueza Costa David,de Azeredo Siqueira Rodrigo,Faradji Raquel N.,Rincón Ramírez Alex,Ré Matías,Fériz Bonelo Karen,Proietti Adrián,Lavalle-González Fernando J.
Abstract
Abstract
Objective
To establish recommendations through the consensus of a Latin American experts panel on the use of the flash glucose monitoring system (fCGM) in people living with type 2 diabetes mellitus (T2DM) regarding the benefits and challenges of using the fCGM.
Methods
An executive committee of experts was created, comprised by a panel of fifteen physicians, including endocrinologists and internal medicine physicians, with expertise in management of adult patients with T2DM. The experts were from various countries: Colombia, Chile, Peru, Mexico, Argentina, and Brazil. The modified Delphi method was used, considering a consensus level of at least 80% of the participants. A seventeen-item instrument was developed to establish recommendations on the use of fCGM in patients with T2DM in Latin American.
Results
The number of glucose scans recommended per day with the fCGM for patients managed with oral antidiabetic drugs or basal insulin was a median of 6 scans per day, and for those managed with multiple insulin doses, a median of 10 scans per day was recommended. Additionally, a holistic and individualized management approach was recommended, taking into account new treatment directions and identifying patients who would benefit from the use of the fCGM.
Conclusion
Continuous use of the fCGM is recommended for people living with T2DM, regardless of their type of treatment. These metrics must be evaluated individually for each patient profile.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Latin American Diabetes Association. ALAD Guidelines on the diagnosis, control and management of type 2 diabetes with evidence based medicine 2019 edition. ALAD. 2019. https://revistaalad.com/guias/5600AX191_guias_alad_2019.pdf
2. International Diabetes Federation. IDF diabetes atlas, 10th edn. Brussels. https://www.diabetesatlas.org.(2021)
3. American Diabetes Association. Standards of care in diabetes. Diabet Care. 2023;46(S1):S1–291.
4. Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F. A view beyond HbA1c: role of continuous glucose monitoring. Diabet Ther. 2019;10(3):853–63. https://doi.org/10.1007/s13300-019-0619-1.
5. Bosi E, Gregori G, Cruciani C, Irace C, Pozzilli P, Buzzetti R. The use of flash glucose monitoring significantly improves glycemic control in type 2 diabetes managed with basal bolus insulin therapy compared to self-monitoring of blood glucose: a prospective observational cohort study. Diabet Res Clin Pract. 2022;183: 109172. https://doi.org/10.1016/j.diabres.2021.109172.